The European Commission has granted market authorization to Sanofi for its insulin aspart biosimilar, making it the first approved biosimilar to NovoRapid for the region.
Sanofi has received marketing authorization for its insulin aspart biosimilar (Insulin aspart Sanofi) from the European Commission, becoming the first insulin aspart biosimilar to be approved in Europe.
Market authorization was granted on June 25 and Sanofi announced it on July 3.
“With Insulin aspart Sanofi, we will serve people with diabetes in a diverse range of age groups. This reflects our continued commitment to individualization of care for people with diabetes,” Alan Divanovic, MD, vice president of medical affairs at Sanofi, told Pharmacy Business.
The biosimilar references Novo Nordisk's NovoRapid and was approved for blood sugar control in adults, adolescents, and children aged 1 and older who have type 1 or type 2 diabetes.
The European Commission’s decision comes after the European Medicines Agency’s Committee for Human Medical Products issued a positive recommendation for approval in May 2020.
The approval was based on data from a clinical development project that involved more than 600 adult patients with type 1 or type 2 diabetes.
Sanofi investigators presented the study results from 3 late-breaking clinical trials at the American Diabetes Association 79th Scientific Sessions in June 2019, showing that Insulin aspart Sanofi was comparable to the reference product in pharmacokinetics, pharmacodynamics, safety, and efficacy.
Sanofi’s Growing Insulin Portfolio
This is Sanofi’s third rapid-acting insulin analog to be approved by European regulators. Its insulin glulisine originator (Apidra) was approved in Europe in 2004, and its insulin lispro follow-on product (Admelog) received European approval in 2017.
“By providing all 3 rapid-acting insulin options in glulisine, lispro, and aspart, Sanofi is expanding the affordability and sustainability of insulin treatments, giving payers, physicians and patients more flexibility,” Divanovic said.
Admelog was approved by FDA in 2017 and launched on the US market in April 2018.
Sanofi also released positive phase 3 clinical results for Toujeo, its follow-on insulin glargine product (Lantus), in pediatric patients in November 2019.
Sanofi is the maker of Lantus, an insulin glargine blockbuster product that is currently facing intense biosimilar competition in Europe and was the first insulin product to have a biosimilar approved there.
In December 2019, Sanofi announced that it would end its research and development efforts on diabetes and cardiovascular drugs in order to focus more on cancer immunotherapies and other biologics, but said that it will continue with its insulin business.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
FDA Draft Guidance Removes Switching Study Requirements for Biosimilar Interchangeability
June 20th 2024The FDA has issued an update to its guidance on requiring switching study data for biosimilars to be granted interchangeability, citing new science that shows these studies aren’t needed to establish biosimilar safety.
British Columbia’s Biosimilar Switching Program Saves $732 Million in 5 Years
June 18th 2024British Columbia's 2019 Biosimilars Initiative, which transitioned over 40,000 patients from costly reference biologics to biosimilars, saved around $732 million in 5 years, maintained comparable health outcomes, and reinvested the savings to improve the province's public payer program.